Tagged with CIS

MEA For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward to 2026, and massive genome projects across the Gulf region are attempting to shift the narrative. Backed by immense sovereign…

USA Tony Zook reflects on how decades in pharmaceutical leadership inform his perspective on diagnostics as the backbone of precision oncology. This discussion traces NeoGenomics’ evolution from a haematology specialist to a broader oncology platform spanning therapy selection, next-generation sequencing (NGS), and molecular residual disease (MRD). Set against the realities of…

USA Precision medicine increasingly depends on diagnostics that can keep pace with therapeutic innovation while remaining accessible in real-world care. Jonathan Arnold reflects on how QIAGEN approaches oncology and emerging hereditary disease programmes by aligning diagnostic development with pharmaceutical pipelines, prioritising decentralisation, and investing in technologies that support both translational insight…

Taiwan Professor Chi-Huey Wong serves as President of the Institute for Biotechnology and Medicine Industry (IBMI) in Taiwan, bringing decades of distinguished experience from top-tier US research institutions including MIT, Scripps Research and his tenure as President of Academia Sinica. With a unique vantage point spanning both American and Taiwanese scientific…

Taiwan With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a biologic therapy worldwide. Now CEO, Chang has overseen the company’s evolution from a single-asset HIV specialist to a globally recognised…

France With over two decades of international experience in the pharmaceutical industry, Olivier Zambelli brings both strategic vision and a deeply human approach to his role as President and General Manager of Astellas France. Joining at a time of profound transformation for the organisation, he is leading the affiliate through a…

Switzerland Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush to meet soaring market demand, and the global industry is scrambling to align with the Trump administration’s threats and incentives…

Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…

France Curium is redefining how radiopharmaceuticals are developed, manufactured, and delivered to patients worldwide. Under the leadership of Ciril Faia, Curium International is advancing a new generation of diagnostic and therapeutic innovations, with particular focus on prostate cancer and neuroendocrine tumours (NET). Through sustained investment in talent, infrastructure, and its newly…

Switzerland Stephan Fritschi, recently appointed CEO at CARBOGEN AMCIS, brings nearly three decades of institutional knowledge to his new position. With 29 years of experience within the organisation, he has witnessed the company’s evolution through multiple market cycles and strategic transformations. His appointment represents continuity in leadership while signalling a new…

USA Michael Hogue, CEO of the American Pharmacists Association (APhA), shares his vision for the future of the pharmacy profession and its evolving role in healthcare. He discusses the strategic priorities for pharmacists in the coming years, emphasizing the need to reshape public perception, expand the role of pharmacists in disease…

Switzerland Emanuele Ostuni, CEO of ARTBIO, delves into the company’s innovative approach to radioligand therapies, focusing on its potential to replace chemotherapy and provide more effective treatment options for patients. Ostuni emphasizes the company’s commitment to precision oncology, with a strong team spread across Switzerland, Norway, USA, and the UK.  …